Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05354765 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Exploration of Adaptive Antitumoral Immune Cells Through Lymphapheresis in Cancer Patients : ALCYTA

Study acronym: ALCYTA
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Sep 3, 2026 to Sep 3, 2027v6
  2. Primary and study completion dates: May 15, 2027 to Sep 3, 2026
    • Start date: Aug 28, 2022 to Aug 31, 2022
    v5
  3. Re-verified, no change to tracked fieldsv4
  4. Eligibility criteria revised
    • Study title expanded, about 1 word
    v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 15, 2022 to Aug 28, 2022
    • Site details revised at 2 of 2 sites
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Institut Curie
43 trials monitored
See 1 trial at risk
The study will evaluate the detection of tumor-antigen specific immune cells in cancer patients in whom the role of the immune system is suspected.
Trial Details
NCT Number NCT05354765
Lead Sponsor Institut Curie
Conditions
(from sponsor)		 Cancer, Immune System or Toxicities Suspected
Related terms Neoplasms
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov